Currently out of the existing stock ratings of Mason Carrico, 56 are a BUY (82.35%), 12 are a HOLD (17.65%).

Mason Carrico

Work Performance Price Targets & Ratings Chart

Analyst Mason Carrico, currently employed at STEPHENS, carries an average stock price target met ratio of 67.54% that have a potential upside of 37.05% achieved within 244 days.

Mason Carrico’s has documented 119 price targets and ratings displayed on 19 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on NTRA, Natera at 13-Nov-2025.

Wall Street Analyst Mason Carrico

Analyst best performing recommendations are on CTKB (CYTEK BIOSCIENCES).
The best stock recommendation documented was for CTKB (CYTEK BIOSCIENCES) at 12/13/2023. The price target of $9 was fulfilled within 2 days with a profit of $0.98 (12.22%) receiving and performance score of 61.1.

Average potential price target upside

of $34.61 (40.33%) on ILMN (ILLUMINA).
of $27.42 (62.17%) on GH (GUARDANT HEALTH).
of $22.88 (21.83%) on NTRA (NATERA).

CSTL Castle Biosciences DMTK DermTech GH Guardant Health OCX OncoCyte Corp VCYT Veracyte AKYA Akoya Biosciences MYGN Myriad Genetics CDNA Caredx NEO NeoGenomics TXG 10X Genomics ILMN Illumina NTRA Natera PACB Pacific Biosciences of California HOLX Hologic CTKB Cytek Biosciences ESTA Establishment Labs Holdings STAA STAAR Surgical Company VCEL Vericel Corp Ord NEON

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Kyle Mikson (CANACCORD)